Our Pipeline
Fe Pharmaceuticals is developing a pipeline of indications for DIBI in serious diseases exacerbated by iron dysregulation. These are diseases where our iron binding polymer platform can provide a unique solution. Our current focus areas include infectious disease, inflammatory diseases, and cancer.
Fe Pharmaceuticals’ pipeline consists of two infectious disease indications in development for IV DIBI, one GI (gastrointestinal) infectious disease indication in proof-of-concept testing for oral DIBI, one oncology indication currently in proof-of-concept testing for IV DIBI, and a veterinary indication for which a Phase 2 study in dogs has been completed (available for licensing).
